Gavin Clark-Gartner
Stock Analyst at Evercore ISI
(4.91)
# 233
Out of 4,996 analysts
232
Total ratings
60.9%
Success rate
38.2%
Average return
Main Sectors:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Reiterated: Hold | $16 → $18 | $14.88 | +20.97% | 7 | Sep 21, 2026 | |
| TRAX First Tracks Biotherapeutics | Initiated Coverage: Buy | $65 | $36.66 | +77.30% | 1 | Sep 18, 2026 | |
| ABBV AbbVie | Rated: Buy | $235 → $260 | $265.08 | -1.92% | 18 | Aug 10, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $21 | $13.75 | +52.73% | 6 | Aug 10, 2026 | |
| DNTH Dianthus Therapeutics | Reiterated: Buy | $120 → $134 | $93.39 | +43.48% | 10 | Aug 10, 2026 | |
| EVMN Evommune | Reiterated: Buy | $55 → $22 | $8.77 | +150.86% | 4 | Aug 10, 2026 | |
| SRPT Sarepta Therapeutics | Reiterated: Hold | $19 | $18.95 | +0.26% | 28 | Aug 10, 2026 | |
| TENX Tenax Therapeutics | Downgraded: Hold | $39 → $5 | $1.90 | +163.16% | 2 | Aug 10, 2026 | |
| TVTX Travere Therapeutics | Reiterated: Buy | $68 → $78 | $59.83 | +30.37% | 9 | Aug 10, 2026 | |
| VRDN Viridian Therapeutics | Reiterated: Buy | $26 | $21.43 | +21.33% | 12 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $329 | $223.13 | +47.45% | 14 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $162 → $170 | $118.34 | +43.65% | 8 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1,059 | $945.82 | +11.97% | 13 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 | $16.23 | +103.33% | 7 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $91 | $33.05 | +175.34% | 8 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.5668 | - | 8 | Jul 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $16.72 | - | 7 | Jul 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $29.67 | +71.89% | 1 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $126 → $138 | $89.32 | +54.50% | 19 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $295 → $300 | $341.75 | -12.22% | 14 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $18 | $11.75 | +53.19% | 4 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $46 | $20.44 | +125.05% | 1 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 → $26 | $37.65 | -30.94% | 5 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 → $17 | $8.57 | +98.37% | 4 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4 | $2.22 | +80.18% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.70 | +194.12% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 | $3.02 | +65.56% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4 | $1.26 | +217.46% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $18 | $3.87 | n/a | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $3.08 | n/a | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $78 | $124.64 | n/a | 1 | Aug 3, 2022 |
Ultragenyx Pharmaceutical
Sep 21, 2026
Reiterated: Hold
Price Target: $16 → $18
Current: $14.88
Upside: +20.97%
First Tracks Biotherapeutics
Sep 18, 2026
Initiated Coverage: Buy
Price Target: $65
Current: $36.66
Upside: +77.30%
AbbVie
Aug 10, 2026
Rated: Buy
Price Target: $235 → $260
Current: $265.08
Upside: -1.92%
COMPASS Pathways
Aug 10, 2026
Reiterated: Buy
Price Target: $21
Current: $13.75
Upside: +52.73%
Dianthus Therapeutics
Aug 10, 2026
Reiterated: Buy
Price Target: $120 → $134
Current: $93.39
Upside: +43.48%
Evommune
Aug 10, 2026
Reiterated: Buy
Price Target: $55 → $22
Current: $8.77
Upside: +150.86%
Sarepta Therapeutics
Aug 10, 2026
Reiterated: Hold
Price Target: $19
Current: $18.95
Upside: +0.26%
Tenax Therapeutics
Aug 10, 2026
Downgraded: Hold
Price Target: $39 → $5
Current: $1.90
Upside: +163.16%
Travere Therapeutics
Aug 10, 2026
Reiterated: Buy
Price Target: $68 → $78
Current: $59.83
Upside: +30.37%
Viridian Therapeutics
Aug 10, 2026
Reiterated: Buy
Price Target: $26
Current: $21.43
Upside: +21.33%
Aug 7, 2026
Reiterated: Buy
Price Target: $329
Current: $223.13
Upside: +47.45%
Aug 7, 2026
Reiterated: Buy
Price Target: $162 → $170
Current: $118.34
Upside: +43.65%
Jul 27, 2026
Reiterated: Buy
Price Target: $1,059
Current: $945.82
Upside: +11.97%
Jul 27, 2026
Reiterated: Buy
Price Target: $33
Current: $16.23
Upside: +103.33%
Jul 9, 2026
Reiterated: Buy
Price Target: $91
Current: $33.05
Upside: +175.34%
Jul 6, 2026
Rated: Hold
Price Target: n/a
Current: $0.5668
Upside: -
Jul 6, 2026
Rated: Hold
Price Target: n/a
Current: $16.72
Upside: -
May 26, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $29.67
Upside: +71.89%
May 7, 2026
Reiterated: Buy
Price Target: $126 → $138
Current: $89.32
Upside: +54.50%
May 5, 2026
Reiterated: Buy
Price Target: $295 → $300
Current: $341.75
Upside: -12.22%
Apr 1, 2026
Reiterated: Buy
Price Target: $20 → $18
Current: $11.75
Upside: +53.19%
Mar 25, 2026
Initiated Coverage: Buy
Price Target: $46
Current: $20.44
Upside: +125.05%
Mar 2, 2026
Reiterated: Buy
Price Target: $24 → $26
Current: $37.65
Upside: -30.94%
Feb 18, 2026
Initiated Coverage: Buy
Price Target: $8 → $17
Current: $8.57
Upside: +98.37%
Dec 17, 2025
Reiterated: Hold
Price Target: $4
Current: $2.22
Upside: +80.18%
Dec 17, 2025
Reiterated: Buy
Price Target: $5
Current: $1.70
Upside: +194.12%
Dec 17, 2025
Reiterated: Hold
Price Target: $5
Current: $3.02
Upside: +65.56%
Dec 17, 2025
Reiterated: Hold
Price Target: $4
Current: $1.26
Upside: +217.46%
Dec 20, 2024
Reiterated: Buy
Price Target: $20 → $18
Current: $3.87
Upside: n/a
May 30, 2023
Reiterated: Buy
Price Target: $10
Current: $3.08
Upside: n/a
Aug 3, 2022
Downgraded: Hold
Price Target: $78
Current: $124.64
Upside: n/a